Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the launch of Cyto-Cellect ® PLUS. In conjunction with the Company’s Cyto-Mine ® platform, the new assay provides a streamlined method to measure antibody production in single cells by rapidly detecting secreted human IgG, enabling the identification and selection of cells with the highest productivity for more efficient cell line development. Cyto-CellectPLUS is a robust and easy-to-use Fluorescence Resonance Energy Transfer (FRET) assay that enables researchers to quantify IgG productivity with high sensitivity.
Expanding on Sphere Fluidics’ original Cyto-Cellect Human IgG kappa (IgGκ) Detection Kit, Cyto-CellectPLUS now detects both the IgG kappa (κ) and lambda (λ) light chains to support a broader range of projects. The assay is fully compatible with existing Cyto-Mine functionality, including single cell dispensing into 96-well and 384-well plates, allowing it to seamlessly integrate into customers’ existing cell line development workflows and conforms to relevant regulatory requirements by being animal-origin-free. Cyto-Mine is an automated platform which integrates single cell screening, sorting, dispensing, imaging, and clone verification in one bench-top system.
Underpinned by the Company’s patented, microfluidic picodroplet technology, it can automatically screen up to 40 million cells in a matter of hours, compared wit.
